Abstract
Neisseria meningitidis is a leading cause of life-threatening invasive meningococcal diseases (IMD). In most populated Canadian provinces, vaccination with the monovalent vaccine (MenC; against serogroup C) is recommended at one year of age. This study aimed to assess various quadrivalent vaccination strategies (MenACWY-TT covering serogroups A, C, W135 and Y) schedule (12 months with and without booster at 12 or 15 years) in Canada compared to the current strategy.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
